This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Andre N, Braguer D, Brasseur G, Goncalves A, Lemesle-Meunier D, et al. 2000. Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells. Cancer Res 60: 5349–53
Andre N, Carre M, Brasseur G, Pourroy B, Kovacic H, et al. 2002. Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Lett 532: 256–60
Azzazy HM, Mansour MM, Kazmierczak SC. 2006. Nanodiagnostics: a new frontier for clinical laboratory medicine. Clin Chem 52: 1238–46
Bangham AD, Standish MM, Watkins JC. 1965a. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13: 238–52
Bangham AD, Standish MM, Weissmann G. 1965b. The action of steroids and streptolysin S on the permeability of phospholipid structures to cations. J Mol Biol 13: 253–9
Boddapati SV, Tongcharoensirikul P, Hanson RN, D'Souza GG, Torchilin VP, Weissig V. 2005. Mitochondriotropic liposomes. J Liposome Res 15: 49–58
Carre M, Carles G, Andre N, Douillard S, Ciccolini J, et al. 2002. Involvement of microtubules and mitochondria in the antagonism of arsenic trioxide on paclitaxel-induced apoptosis. Biochem Pharmacol 63: 1831–42
Cheng SM, Pabba S, Torchilin VP, Fowle W, Kimpfler A, Schubert R, Weissig V. 2005. Towards mitochondria-specific delivery of apoptosis-inducing agents: DQAsomal incorporated paclitaxel. J Drug Deliv Sci Technol 15: 81–6
Cheng SM, Boddapati SV, D'Souza GM, Weissig V. 2007. DQAsomes as Mitochondria-Targeted Nano-Carriers for Anticancer Drugs. In Amiji, pp. M Nanotechnology for Cancer Therapeutics, ed. CRC/Taylor & Francis Group LLCFL, USA/PA, USA: 787–802.
Costantini P, Jacotot E, Decaudin D, Kroemer G. 2000a. Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 92: 1042–53
Costantini P, Jacotot E, Decaudin D, Kroemer G. 2000b. Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 92: 1042–53
Dauty E, Verkman AS. 2005. Actin cytoskeleton as the principal determinant of size-dependent DNA mobility in cytoplasm: a new barrier for non-viral gene delivery. J Biol Chem 280: 7823–8
Dias N, Bailly C. 2005. Drugs targeting mitochondrial functions to control tumor cell growth. Biochem Pharmacol 70: 1–12
D'Souza GG, Rammohan R, Cheng SM, Torchilin VP, Weissig V. 2003. DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells. J Control Release 92: 189–97
D'Souza GG, Boddapati SV, Weissig V. 2005. Mitochondrial leader sequence-plasmid DNA conjugates delivered into mammalian cells by DQAsomes co-localize with mitochondria. Mitochondrion 5: 352–8
D'Souza GG, Boddapati SV, Weissig V. 2007. Gene therapy of the other genome: the challenges of treating mitochondrial DNA defects. Pharm Res 24: 228–38
Everts M. 2007. Thermal scalpel to target cancer. Expert Rev Med Devices 4: 131–6
Fantin VR, Berardi MJ, Scorrano L, Korsmeyer SJ, Leder P. 2002. A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. Cancer Cell 2: 29–42
Ferlini C, Raspaglio G, Mozzetti S, Distefano M, Filippetti F, et al. 2003. Bcl-2 Down-Regulation Is a Novel Mechanism of Paclitaxel Resistance. Mol Pharmacol 64: 51–8
Fujino M, Li XK, Kitazawa Y, Guo L, Kawasaki M, et al. 2002. Distinct pathways of apoptosis triggered by FTY720, etoposide, and anti-Fas antibody in human T-lymphoma cell line (Jurkat cells). J Pharmacol Exp Ther 300: 939–45
Fulda S, Susin SA, Kroemer G, Debatin KM. 1998. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res 58: 4453–60
Gambacorta A, Gliozi A, Rosa M. De1995. Archaeal lipids and their biotechnological applications. World J Microbiol Biotechnol 11: 115–31
Hockenbery DM. 2002. A mitochondrial Achilles' heel in cancer? Cancer Cell 2: 1–2
Horobin RW. 2001. Uptake, distribution and accumulation of dyes and fluorescent probes within living cells: a structure-activity modelling approach. Adv Colour Sci Technol 4: 101–7
Horobin RW, Trapp S, Weissig V. 2007. Mitochondriotropics: a review of their mode of action, and their application fro drug and DNA delivery to mammalian mitochondria. J Control Release 121125–136:
Itoh M, Noutomi T, Toyota H, Mizuguchi J. 2003. Etoposide-mediated sensitization of squamous cell carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced loss in mitochondrial membrane potential. Oral Oncol 39: 269–76
Ju-Nam Y, Bricklebank N, Allen DW, Gardiner PH, Light ME, Hursthouse MB. 2006. Phosphonioalkylthiosulfate zwitterions – new masked thiol ligands for the formation of cationic functionalised gold nanoparticles. Org Biomol Chem 4: 4345–51
Kidd JF, Pilkington MF, Schell MJ, Fogarty KE, Skepper JN, et al. 2002. Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore. J Biol Chem 277: 6504–10
Lasch J, Meye A, Taubert H, Koelsch R, Mansa-ard J, Weissig V. 1999. Dequalinium vesicles form stable complexes with plasmid DNA which are protected from DNase attack. Biol Chem 380: 647–52
Lukacs GL, Haggie P, Seksek O, Lechardeur D, Freedman N, Verkman AS. 2000. Size-dependent DNA mobility in cytoplasm and nucleus. J Biol Chem 275: 1625–9
Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. 2000. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65: 271–84
Marchetti P, Zamzami N, Joseph B, Schraen-Maschke S, Mereau-Richard C, et al. 1999. The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus. Cancer Res 59: 6257–66
Matsumura Y. 2007. Preclinical and clinical studies of anticancer drug-incorporated polymeric micelles. J Drug Target 15: 507–17
Matsumura Y, Oda T, Maeda H. 1987. [General mechanism of intratumor accumulation of macromolecules: advantage of macromolecular therapeutics]. Gan To Kagaku Ryoho 14: 821–9
Medda R, Jakobs S, Hell SW, Bewersdorf J. 2006. 4Pi microscopy of quantum dot-labeled cellular structures. J Struct Biol 156: 517–23
Niedermann G, Weissig V, Sternberg B, Lasch J. 1991. Carboxyacyl derivatives of cardiolipin as four-tailed hydrophobic anchors for the covalent coupling of hydrophilic proteins to liposomes. Biochim Biophys Acta 1070: 401–8
Rowe TC, Weissig V, Lawrence JW. 2001. Mitochondrial DNA metabolism targeting drugs. Adv Drug Deliv Rev 49: 175–87
Seksek O, Biwersi J, Verkman AS. 1997. Translational diffusion of macromolecule-sized solutes in cytoplasm and nucleus. J Cell Biol 138: 131–42
Torchilin VP, Weissig V, Martin FJ, Heath TD, New RRC. 2003. Surface Modification of Liposomes. In Torchilin, VP Weissig, V, Liposomes – A Practical Approach, ed. Oxford University pressOxford: pp. 193–230.
Trapp S, Horobin RW. 2005. A predictive model for the selective accumulation of chemicals in tumor cells. Eur Biophys J 34: 959–66
Vaughan EE, Dean DA. 2006. Intracellular trafficking of plasmids during transfection is mediated by microtubules. Mol Ther 13: 422–8
Weissig V, Gregoriadis G. 1993. Coupling of Aminogroup-Bearing Ligands to Liposomes. In Gregoriadis, pp. G Liposome Technology, ed. CRCBoca Raton, Ann Arbor, London, Tokyo: 231–48.
Weissig V, Lasch J, Klibanov AL, Torchilin VP. 1986. A new hydrophobic anchor for the attachment of proteins to liposomal membranes. FEBS Lett 202: 86–90
Weissig V, Lasch J, Gregoriadis G. 1989. Covalent coupling of sugars to liposomes. Biochim Biophys Acta 1003: 54–7
Weissig V, Lasch J, Erdos G, Meyer HW, Rowe TC, Hughes J. 1998. DQAsomes: a novel potential drug and gene delivery system made from Dequalinium. Pharm Res 15: 334–7
Weissig V, Lizano C, Torchilin VP. 2000. Selective DNA release from DQAsome/DNA complexes at mitochondria-like membranes. Drug Deliv 7: 1–5
Weissig V, D'Souza GG, Torchilin VP. 2001. DQAsome/DNA complexes release DNA upon contact with isolated mouse liver mitochondria. J Control Release 75: 401–8
Weissig V, Cheng S-M, D'Souza G. 2004. Mitochondrial Pharmaceutics. Mitochondrion 3: 229–44
Weissig V, Boddapati SV, D'Souza GGM, Horobin RH. 2007a. Functionalization of Pharmaceutical Nanocarriers for Mitochondria-targeted Drug and DNA Delivery. InMultifunctional Pharmaceutical Nanocarriers, ed. VP Torchilin: Springer: Berlin
Weissig V, Boddapati SV, Jabre L, D'Souza GGM. 2007b. Mitochondria-specific nanotechnology. Nanomedicine 2: 275–85
Zorov DB, Kobrinsky E, Juhaszova M, Sollott SJ. 2004. Examining intracellular organelle function using fluorescent probes: from animalcules to quantum dots. Circ Res 95: 239–52
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2009 Springer Science + Business Media, LLC
About this chapter
Cite this chapter
Weissig, V., D’Souza, G.G.M., Cheng, SM., Boddapati, S. (2009). Mitochondrial Nanotechnology for Cancer Therapy. In: Mitochondria and Cancer. Springer, New York, NY. https://doi.org/10.1007/978-0-387-84835-8_14
Download citation
DOI: https://doi.org/10.1007/978-0-387-84835-8_14
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-84834-1
Online ISBN: 978-0-387-84835-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)